量身定制的干预措施,以改善与帕金森病的老年患者的药物坚持:随机对照试验 (AdhCare) 的研究协议
Sarah Mendorf1, Ulrike Teschner2, Thomas Lehmann3
1Department of Neurology, Jena University Hospital, Jena, Germany. sarah.mendorf@med.uni-jena.de.
Trials
|October 12, 2023
概括
量身定制的干预措施可以改善帕金森病 (PD) 患者的药物坚持. 这项研究将个性化方法 (AdhCare) 与老年PD患者的常规护理进行比较,评估其对坚持和生活质量的影响.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 对患有帕金森病 (PD) 等慢性疾病的患者来说,不坚持药物治疗是一个重大挑战.
- 目前改善依守的干预措施的有效性有限,这凸显了个性化策略的必要性.
- 量身定制的方法,而不是一种适合所有人的方法,可能更有利于提高药物坚持.
研究的目的:
- 评估AdhCare的疗效,一个量身定制的干预措施,改善PD的老年患者的药物坚持.
- 为了比较AdhCare干预与日常护理在坚持,运动功能和生活质量方面.
主要方法:
- 一个随机的,受控的,三重盲试验,涉及老年PD患者 (每组64名参与者).
- 根据个人不坚持的原因 (例如,遗忘,缺乏知识) 量身定制的干预.
- 运动功能的评估,生活质量,以及在基线,3个月和6个月的坚持.
主要成果:
- 结果正在等待,并将从正在进行的试验中进行分析.
- 这项研究旨在量化定制干预和常规护理组之间坚持率的差异.
- 运动功能和生活质量的变化将在两组之间进行比较.
结论:
- 该研究预计将提供关于针对老年PD患者药物坚持量身定制干预措施有效性的证据.
- 调查结果将为医疗保健专业人员和政策制定者提供关于管理慢性病的最佳策略的信息.
- 这项研究有助于理解神经系统疾病中的个性化医疗方法.
相关概念视频
01:24Parkinson's Disease: Treatment
283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
01:28Drug Therapy
49
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
49
01:15Parkinson's Disease: Overview
579
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
579
01:22Alzheimer's Disease: Treatment
211
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
211
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11